Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257932 | 0.95 | SLC5A2 (0.85) | SLC5A2SLC5A1 | |
| SCHEMBL2257125 | 0.93 | SLC5A2 (0.77) | SLC5A2SLC5A1 | |
| SCHEMBL29535770 | 0.93 | SLC5A2 (0.77) | SLC5A2SLC5A1 | |
| SCHEMBL2255654 | 0.93 | SLC5A2 (0.77) | SLC5A2SLC5A1 | |
| SCHEMBL2256721 | 0.92 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL2256225 | 0.92 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL2255129 | 0.92 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL2253384 | 0.91 | SLC5A2 (0.89) | SLC5A2SLC5A1 | |
| SCHEMBL14435199 | 0.90 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL13940726 | 0.89 | SLC5A2 (0.62) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1354888-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL (JP) | 2009-05-20 | — | — | EP | claimed |
| EP-1912656-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2008-04-23 | — | — | EP | claimed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | claimed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | claimed |
| US-7084123-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | claimed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | claimed |
| CN-114450011-A | Compositions and methods for treating metabolic disorders | 阿沃林特有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-7989424-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| WO-2007014895-A2 | METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-7084123-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20060094667-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. | 2006-05-04 | — | — | US | disclosed |
| US-20060035847-A1 | Glucopyranosyloxyprazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. | 2006-02-16 | — | — | US | disclosed |
| US-20060025352-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | Kissei Pharmaceutical Co.,Ltd. | 2006-02-02 | — | — | US | disclosed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | SLC5A2 6/4885SLC5A1 4/4885 |
| US-20060035847-A1 | Glucopyranosyloxyprazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20060094667-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20060025352-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.